The 77th Scientific Sessions of the American Diabetes Association is underway in San Diego, CA from June 9-13, 2017.
Xultophy 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight in adults with type 2 diabetes compared to treatment with basal-bolus therapy
Novo Nordisk announced Saturday that new results from the phase 3b DUAL VII clinical trial showed that Xultophy 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight in adults with type 2 diabetes compared to treatment with basal-bolus therapy.
In DUAL VII, Xultophy 100/3.6 demonstrated non-inferiority in lowering A1C when compared to insulin glargine U100 in combination with insulin aspart.
The objective of non-inferiority trials is to compare a novel treatment to an active treatment with a view of demonstrating that it is not clinically worse with regards to a specified endpoint.
Those treated with #Xultophy 100/3.6 versus basal-bolus therapy also: Reached similar glycemic targets; demonstrated an 89% reduction in severe or blood glucose confirmed symptomatic hypoglycemic events and a 92% reduction for nocturnal severe or blood glucose confirmed symptomatic hypoglycemic events; experienced a weight reduction of 0.93 kg compared with a weight gain of 2.64 kg for people treated with the basal-bolus regimen; achieved glycemic control with no hypoglycemic episodes and no weight gain in the last 12 weeks.
A basal-bolus routine involves taking a longer acting form of insulin to keep blood glucose levels stable through periods of fasting and separate injections of shorter acting insulin to prevent rises in blood glucose levels resulting from meals.
Furthermore, patients treated with Xultophy 100/3.6 required a lower daily insulin dose compared with the basal-bolus treatment group — 40 units vs 84 units.
Adverse events were similar across both treatment groups. The safety profile of Xultophy 100/3.6 in DUAL VII was generally consistent with previous Xultophy 100/3.6 clinical trials.
closed at $42.84. It has a 52-week trading range of $30.89 to $57.41.
To read stories similar to this, sign up for a free trial membership to Stockwinners; be sure to check the Market Radar section.
The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.